More Videos
SPECIAL REPORT
MOST SHARED
- The Executive Job Search
- Where Do Pardoned Turkeys Go?
- Chinese Overcapacity is Worsening, EU Chamber Warns
- Salvation Army's Kettles Now Credit Card-Ready
- Activision Prepares to Double Dip on ‘Modern Warfare 2’
- US Mint to Suspend American Eagle Gold 1-Ounce Coins
- Dubai Debt Delay Rattles Stock, Bond Markets
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Topless Business Is Taking Off
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- Share Trading on London Stock Exchange Frozen
- Dubai Debt Delay Rattles Stock, Bond Markets
- Fannie Mae to Tighten Lending Standards: Report
- China Overcapacity Worsening, EU Chamber Warns
- Investing in Good Karma – and Making a Profit
- China Unveils Carbon Target Ahead of Copenhagen
- Wal-Mart Price Pressure Hurts China Workers: Report
- Black Friday to Avoid Red Ink; Greenback Gets the Blues
- Bankruptcies Jump, Hitting Highest Level in Four Years
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
 |
]shares have fallen to yet another new low intra-day and have crossed another threshold--as I write this they're under $19. But Eli Lilly is the biggest dollar and percentage gainer on an otherwise weak pharma tape. This morning Cowen and Company big pharma analyst Steve Scala upgraded LLY[LLY
Loading...
()
] to Outperform (euphemism for Buy), Novartis [NVS
Loading...
()
]to Outperform and downgraded Bristol-Myers Squibb [BMY
Loading...
()
] to Neutral (euphemism for Hold). His call definitely seems to be moving LLY and BMY, but not NVS, which coincidentally is holding a deep-dive meeting today for analysts and investors into its vaccine portfolio and pipeline.
Scala is basing his bullishness on Lilly primarily on the pending Food and Drug Administration decision on whether to approve the company's experimental bloodthinner Effient. I wonder if the FDA does approve the drug whether it'll let Lilly use that name because it might not like the connotation of Effient implying that it is efficient. Scala places 70/30 odds on approval of the pill.
He doesn't mention it in his upgrade note, but LLY could possibly move on major data due out over this coming weekend and/or early next week at the American Diabetes Association meeting in San Francisco. LLY, Amylin Pharmaceuticals [AMLN
Loading...
()
] and Alkermes [ALKS
Loading...
()
] will be presenting new test results on their developmental once-a-week injectable diabetes drug Byetta. Many analysts believe the product could become a multi-billion-dollar blockbuster.
After a brief recovery from my ASCO hangover here at CNBC HQ in New Jersey, I'll be heading to ADA this weekend and will be reporting live from there on Monday. Novo Nordisk [NVO
Loading...
()
] will also be out with data there on its developmental diabetes drug that analysts have high hopes for. It's a mouthful: liraglutide. I wish they'd give it a commercial name already.
And unlike most scientific conferences that frontload the meetings with the headline-grabbing stuff during the first day or two, ADA stretches things out a bit and backloads its meeting (perhaps to keep attendees there as long as possible?) with embargoes lifting on big data even on the last day.
Some analysts say one to watch on Tuesday morning could be a diabetes/obesity drug in late-stage development at a small biotech, Vivus [VVUS
Loading...
()
] .
Tomorrow morning on "Squawk on the Street" at around 10:40 ET I'll be doing a curtain-raiser report on ADA.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes